5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study

The extracted text reports a single longitudinal case study of a 23-year-old female with chronic, treatment‑refractory post‑traumatic stress disorder (PTSD) arising from repeated sexual abuse during adolescence. Prior interventions included multiple psychotherapies—prolonged exposure (10 sessions), cognitive processing therapy (12 sessions) and stress inoculation training (8 sessions)—which the patient described as producing only marginal benefit. She was treated pharmacologically with sertraline (initiated at 25 mg then 50 mg daily) but discontinued after intolerable side effects and inadequate response, and was subsequently prescribed trazodone (75 mg daily) for insomnia with partial symptom relief. She had no prior psychedelic use and used cannabis intermittently for anxiety. The COVID‑19 pandemic and associated social isolation were described as aggravating her symptoms and suicide risk. Motivated by ongoing distress, prior treatment resistance, information the patient had read about 5‑MeO‑DMT, recent decriminalisation in her state, and access to a trauma‑informed facilitator, the patient pursued self‑treatment with vaporised bufotoxin from the Sonoran Desert toad (Incilius alvarius). The extracted text estimates the toad secretion delivered approximately 10–15 mg of 5‑MeO‑DMT. Details about the exact administration setting and the presence or form of psychological preparation/integration beyond referral to a facilitator are limited in the extraction. Follow‑up assessments were conducted by a supporting clinician at next‑day, 1‑, 3‑, 6‑, and 12‑month time points; the extraction does not clearly report standardised instruments used or the full assessment protocol in the Methods section.

According to the extracted Conclusion, a single inhaled dose of bufotoxin containing 5‑MeO‑DMT produced clinically significant reductions in PTSD symptoms by the next day, with improvements maintained at 1‑, 3‑, 6‑, and 12‑month follow‑ups as monitored by the clinician. The patient also reported marked and durable reductions in hopelessness and suicide risk, and clinician observations indicated improved global functioning. No drug‑related serious adverse events were reported. Physiologically, administration was associated with nominal increases in blood pressure and heart rate but no change in oxygen saturation. Subjective acute effects included overwhelming intensity and nausea. The patient experienced a profound mystical or 'complete' mystical experience characterised by ego dissolution, unity and intense affective content; she rated the experience as both profoundly meaningful and challenging. Perceptual phenomenology reportedly included more visual content than commonly described for 5‑MeO‑DMT—initial colours that faded into transcendent light. At the 3‑month follow‑up the patient partially regressed: new‑onset night terrors occurred (the patient could not recall their content), and scores on measures were higher at that time point relative to other follow‑ups but remained below clinical thresholds. The authors discuss this episode as either a delayed adverse reactivation (a re‑experiencing of drug‑state elements) or a waning of therapeutic effect; they note that reactivation has been associated with female sex, structured group dosing, and a strong mystical experience, and state that these factors applied to the case, though the extraction does not clearly describe whether dosing occurred in a group format.

J. and colleagues interpret the case as evidence that a single inhaled dose of 5‑MeO‑DMT (via toad bufotoxin) can be associated with rapid, clinically meaningful reductions in PTSD symptoms and suicidal ideation in a person with chronic, treatment‑resistant PTSD, with effects persisting up to 12 months in this individual. They propose that the therapeutic response may be partly mediated by the intense mystical or noetic qualities of the experience—states characterised by transcendence, ego dissolution and profound personal meaning—which have been linked in prior studies to therapeutic benefit following serotonergic psychedelics. The authors situate the case within existing, primarily naturalistic and retrospective literature reporting symptom improvements after 5‑MeO‑DMT, ibogaine, or other psychedelic exposures (including surveys and observational studies noting high rates of mystical experience and associations between mystical intensity and symptom change). They also acknowledge phenomena described in earlier work such as 'reactivation' or flashback‑like experiences and consider the 3‑month night terrors in this case as consistent with that literature or alternatively with a transient loss of therapeutic gains. Key limitations noted by the authors include the single‑subject design and consequent non‑generalizability, reliance on methods that are not clinically standard (self‑initiated, naturalistic toad secretion use), and incomplete ability to attribute adverse events (the night terrors) definitively to 5‑MeO‑DMT. They report that no serious adverse events occurred but acknowledge subjective overwhelm and physiological changes (blood pressure, heart rate). The authors recommend further research to replicate and extend these findings, to better characterise 5‑MeO‑DMT phenomenology compared with other psychedelics, and to inform facilitation and harm‑reduction practices for clinical targeting of PTSD and chronic stress pathology.

J. and colleagues conclude that, in this single longitudinal case, a single inhaled dose of bufotoxin containing 5‑MeO‑DMT was associated with rapid and durable reductions in PTSD symptoms, hopelessness and suicide risk, and was generally tolerated without drug‑related serious adverse events. They emphasise that these observations are inherently limited and non‑generalizable and call for further controlled research to confirm efficacy, delineate mechanisms (including the role of mystical experience), and improve safety and facilitation practices.